...
首页> 外文期刊>Clinical and vaccine immunology: CVI >Prolonged Protection against Intranasal Challenge with Influenza Virus following Systemic Immunization or Combinations of Mucosal and Systemic Immunizations with a Heat-Labile Toxin Mutant
【24h】

Prolonged Protection against Intranasal Challenge with Influenza Virus following Systemic Immunization or Combinations of Mucosal and Systemic Immunizations with a Heat-Labile Toxin Mutant

机译:全身免疫或粘膜和全身免疫与不耐热毒素突变体联合使用后,针对流感病毒的鼻内攻击提供了长期保护。

获取原文
           

摘要

Seasonal influenza virus infections cause considerable morbidity and mortality in the world, and there is a serious threat of a pandemic influenza with the potential to cause millions of deaths. Therefore, practical influenza vaccines and vaccination strategies that can confer protection against intranasal infection with influenza viruses are needed. In this study, we demonstrate that using LTK63, a nontoxic mutant of the heat-labile toxin from Escherichia coli, as an adjuvant for both mucosal and systemic immunizations, systemic (intramuscular) immunization or combinations of mucosal (intranasal) and intramuscular immunizations protected mice against intranasal challenge with a lethal dose of live influenza virus at 3.5 months after the second immunization.
机译:季节性流感病毒感染在世界范围内引起相当高的发病率和死亡率,并且存在大流行性流感的严重威胁,有可能导致数百万人死亡。因此,需要实用的流感疫苗和疫苗接种策略,这些疫苗和疫苗接种策略可以针对流感病毒在鼻内感染提供保护。在这项研究中,我们证明了使用LTK63(一种来自大肠杆菌的热不稳定毒素的无毒突变体)作为粘膜和全身免疫,全身(肌内)免疫或粘膜(在第二次免疫后3.5个月,用致死剂量的活流感病毒保护小鼠免受鼻内攻击。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号